A Dose-Escalating Study of Obinutuzumab in Patients With CD20+ Malignant Disease (GAUGUIN)

Lymphoma Clinical Trial

Official title:

An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00517530
• Other study ID #: BO20999
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: August 16, 2007
• Last updated: August 19, 2015
• Start date: September 2007
• Est. completion date: November 2013

Study information

• Verified date: August 2015
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Paul-Ehrlich-Institut
• Study type: Interventional

Clinical Trial Summary

The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in participants with CD20+ (tumor-infiltrating lymphocytic) Malignant Disease, including B-cell chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). The primary objective for the phase II part of the study is to investigate the efficacy and safety of one dose of obinutuzumab in participants with relapsed/refractory CLL and NHL that is, in turn, either indolent (iNHL) or aggressive (aNHL).

It is an open label dose escalating study in phase I and open label in phase II, but the two doses in iNHL & aNHL are randomized (to high or low dose of the same open label treatment). CLL was not randomized as only one dose level was used.

Participants with a response who might gain additional benefit from being treated again in the opinion of the investigator may be enrolled in a Retreatment Period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: November 2013
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients, >=18 years of age;

• Phase 1 only: CD20+ malignant disease (B-cell lymphoma or B-CLL);

• Phase 2 only: relapsed or refractory indolent NHL, relapsed or refractory aggressive NHL or relapsed or refractory B-CLL

• Have a clinical indication for treatment as determined by the investigator

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

• Life expectancy >12 weeks

Exclusion Criteria:

• Prior use of any investigational antibody therapy or other agent within 6 months of study start;

• Prior use of any anti-cancer vaccine;

• Prior use of standard anti-lymphoma/leukemia therapy or radiation therapy within 4 weeks of enrollment;

• Prior use of MabThera (rituximab) within 8 weeks of study entry;

• Prior administration of radioimmunotherapy 3 months prior to study entry;

• Central nervous system (CNS) lymphoma.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma

Intervention

Drug:
• Obinutuzumab
Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study	Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.	Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)	No
Primary	Percentage of Participants With Best Overall Response in Phase II of the Study	Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)	by Cutoff Date: 31MAR2012 (within 3 years, 4 months)	No
Secondary	Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study	A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.	by Cutoff Date: 31MAR2012 (within 3 years, 4 months)	No
Secondary	Percentage of Participants With Partial Response (PR) in Phase II of the Study	A PR was defined as a >=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by >=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.	by Cutoff Date: 31MAR2012 (within 3 years, 4 months)	No
Secondary	Progression-free Survival (PFS) in Phase II of the Study	PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as >= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A >= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of < 1.0 cm must increase by >= 50% and to a size of 1.5×1.5 cm or > 1.5 cm in the longest axis. (2) Appearance of any new lesion > 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.	by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)	No
Secondary	Duration of Response by Disease Type in Phase II of the Study	Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as >= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A >= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of < 1.0 cm must increase by >= 50% and to a size of 1.5×1.5 cm or > 1.5 cm in the longest axis. (2) Appearance of any new lesion > 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.	by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)	No
Secondary	Participants With Event-Free Survival (EFS) in Phase II of the Study	EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.	by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)	No
Secondary	Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study	B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.	by the end of Phase II (within 3 years, 4 months)	No
Secondary	Percentage of Retreated Participants With Response	Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.	by Cutoff Date: 25NOV2013 (within 4 years, 2 months)	No